RUNX1T1 and acute myeloid leukemia: In about 20% of patients with AML, distinct fusion genes are approachable for MRD monitoring, with most of them expressed by the core-binding factor (CBF) AML (RUNX1-RUNX1T1 and CBFB-MYH11 fusion genes).